Roche Secures NMPA Approval for Emicizumab and Satralizumab in China for Hemophilia A and NMOSD

On May 7, the website of China’s National Medical Products Administration (NMPA) showed that two new drugs under Roche received drug approval documents. The approved drugs are emicizumab for patients with hemophilia A and satralizumab for patients with NMOSD.

It is understood that emicizumab is the first prophylactic treatment for hemophilia A in patients with or without factor VIII inhibitors; satralizumab is the first subcutaneous therapy for aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).